📣 VC round data is live. Check it out!
- Public Comps
- PhotoCure
PhotoCure Valuation Multiples
Discover revenue and EBITDA valuation multiples for PhotoCure and similar public comparables like OnKure Therapeutics, Galectin Therapeutics, Milestone Pharmaceuticals, Hyloris Pharmaceuticals and more.
PhotoCure Overview
About PhotoCure
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
Founded
1997
HQ

Employees
101
Website
Financials (LTM)
EV
$148M
Valuation Multiples
Start free trialPhotoCure Financials
PhotoCure reported last 12-month revenue of $63M and EBITDA of $7M.
In the same LTM period, PhotoCure generated $58M in gross profit, $7M in EBITDA, and $4M in net income.
Revenue (LTM)
PhotoCure P&L
In the most recent fiscal year, PhotoCure reported revenue of $58M and EBITDA of $6M.
PhotoCure is unprofitable as of last fiscal year, with gross margin of 92%, EBITDA margin of 10%, and net margin of (0%).
Financial data powered by Morningstar, Inc.
PhotoCure Stock Performance
PhotoCure has current market cap of $173M, and enterprise value of $148M.
Market Cap Evolution
PhotoCure's stock price is $6.48.
PhotoCure share price decreased by 3.3% in the last 30 days, and increased by 14.8% in the last year.
PhotoCure has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $148M | $173M | -3.3% | -3.3% | 2.5% | 14.8% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPhotoCure Valuation Multiples
PhotoCure trades at 2.4x EV/Revenue multiple, and 19.8x EV/EBITDA.
EV / Revenue (LTM)
PhotoCure Financial Valuation Multiples
As of June 2, 2026, PhotoCure has market cap of $173M and EV of $148M.
PhotoCure has a P/E ratio of 40.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PhotoCure Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


PhotoCure Margins & Growth Rates
PhotoCure grew revenue by 24% and EBITDA by 65% in the last fiscal year.
In the most recent fiscal year, PhotoCure reported gross margin of 92%, EBITDA margin of 10%, and net margin of (0%).
PhotoCure Margins
PhotoCure Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
PhotoCure Operational KPIs
PhotoCure's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.5M for the same period.
PhotoCure's Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PhotoCure's Rule of X is 74% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
PhotoCure Competitors
PhotoCure competitors include OnKure Therapeutics, Galectin Therapeutics, Milestone Pharmaceuticals, Hyloris Pharmaceuticals, Innate Pharma, Journey Medical, MediWound, Tiziana Life Sciences, NRX Pharmaceuticals and Mycenax Biotech.
Most PhotoCure public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | (91.4x) | 0.3x | - | |||
| - | - | (14.6x) | (14.5x) | |||
| 29.5x | 11.8x | (0.8x) | - | |||
| 13.1x | 8.0x | (22.4x) | (11.5x) | |||
| 15.7x | 7.7x | (4.9x) | 5.4x | |||
| 2.7x | 2.4x | 57.7x | 25.9x | |||
| 8.3x | 7.1x | (6.9x) | (5.5x) | |||
| - | - | (9.6x) | - | |||
This data is available for Pro users. Sign up to see all PhotoCure competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PhotoCure
| When was PhotoCure founded? | PhotoCure was founded in 1997. |
| Where is PhotoCure headquartered? | PhotoCure is headquartered in Norway. |
| How many employees does PhotoCure have? | As of today, PhotoCure has over 101 employees. |
| Who is the CEO of PhotoCure? | PhotoCure's CEO is Daniel Schneider. |
| Is PhotoCure publicly listed? | Yes, PhotoCure is a public company listed on Oslo Børs. |
| What is the stock symbol of PhotoCure? | PhotoCure trades under PHO ticker. |
| When did PhotoCure go public? | PhotoCure went public in 2000. |
| Who are competitors of PhotoCure? | PhotoCure main competitors include OnKure Therapeutics, Galectin Therapeutics, Milestone Pharmaceuticals, Hyloris Pharmaceuticals, Innate Pharma, Journey Medical, MediWound, Tiziana Life Sciences, NRX Pharmaceuticals, Mycenax Biotech. |
| What is the current market cap of PhotoCure? | PhotoCure's current market cap is $173M. |
| What is the current revenue of PhotoCure? | PhotoCure's last 12 months revenue is $63M. |
| What is the current revenue growth of PhotoCure? | PhotoCure revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of PhotoCure? | Current revenue multiple of PhotoCure is 2.4x. |
| What is the current EBITDA of PhotoCure? | PhotoCure's last 12 months EBITDA is $7M. |
| What is PhotoCure's EBITDA margin? | PhotoCure's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of PhotoCure? | Current EBITDA multiple of PhotoCure is 19.8x. |
| What is the current FCF of PhotoCure? | PhotoCure's last 12 months FCF is $3M. |
| What is PhotoCure's FCF margin? | PhotoCure's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of PhotoCure? | Current FCF multiple of PhotoCure is 55.9x. |
| How many companies PhotoCure has acquired to date? | PhotoCure hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies PhotoCure has invested to date? | PhotoCure hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to PhotoCure
Lists including PhotoCure
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.